Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
VERONE
Venetoclax in Chronic Lymphocytic Leukemia Effectiveness and Real-life Treatment Management
1 other identifier
observational
269
1 country
60
Brief Summary
This study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Longer than P75 for all trials
60 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 24, 2018
CompletedFirst Posted
Study publicly available on registry
January 30, 2018
CompletedStudy Start
First participant enrolled
March 9, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
CompletedJuly 16, 2025
July 1, 2025
8.2 years
January 24, 2018
July 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Best Response of Venetoclax in Participants with Chronic Lymphocytic Leukemia (CLL) up to 12 Months
The best response is defined as the best response observed during the first year of study treatment among the possible responses to treatment: Complete Response (CR), CR with incomplete bone marrow recovery (CRi), nodular Partial Response (nPR), Partial Response (PR), Stable Disease (SD), or Disease Progression (DP).
Up to approximately 12 months
Secondary Outcomes (12)
Time To Next Treatment
Up to approximately 48 months
Time to First Response to Treatment (TTR)
Up to approximately 24 months
Minimal Residual Disease
Up to approximately 24 months
Overall Response Rate (ORR)
Up to approximately 24 months
Change in Score of EuroQol 5 Dimensions (EQ-5D-5L)
Up to approximately 24 months
- +7 more secondary outcomes
Study Arms (1)
Patients with Chronic Lymphocytic Leukemia (CLL)
Patients with diagnosed CLL and eligible to venetoclax as per label
Eligibility Criteria
Adult patients starting venetoclax treatment for CLL.
You may qualify if:
- Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
- Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
- Participants the physician believes he can personally follow over all the study period.
- Participants who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control.
You may not qualify if:
- \- Participating in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (60)
CH Cannes - les Broussailles /ID# 201108
Cannes, Alpes-Maritimes, 06414, France
CH CARCASSONNE - Antoine Gayraud /ID# 202530
Carcassonne, Aude, 11000, France
CHU Clermont-Ferrand /ID# 170736
Clermont, Auvergne-Rhône-Alpes, 63100, France
Clinique Pole santé République /ID# 204658
Clermont-Ferrand, Auvergne, 63050, France
CH de la Haute-Saône - Vesoul /ID# 205150
Vesoul, Bourgogne-Franche-Comté, 70014, France
CHU de RENNES /ID# 169944
Rennes, Brittany Region, 35033, France
CHU de Besancon - Jean Minjoz /ID# 170721
Besançon, Doubs, 25030, France
Centre Hospitalier de Cornouaille /ID# 169937
Quimper, Finistere, 29000, France
CHU Limoges - Dupuytren 1 /ID# 200193
Limoges, Franche-Comte, 87042, France
Institut Bergonie /ID# 170746
Bordeaux, Gironde, 33000, France
CH Roubaix - Hopital Victor Provo /ID# 170909
Roubaix, Hauts-de-France, 59100, France
CHU Montpellier - Hopital Saint Eloi /ID# 200192
Montpellier, Herault, 34295, France
CH de Saint-Malo - Hôpital Broussais /ID# 169935
St-Malo, Ille-et-Vilaine, 35400, France
CHRU Tours - Hopital Bretonneau /ID# 169469
Tours, Indre-et-Loire, 37044, France
CHU Grenoble - Hopital Michallon /ID# 170741
La Tronche, Isere, 38700, France
CHU Reims - Hôpital Robert Debre /ID# 170917
Reims, Marne, 51092, France
CHRU Nancy - Hopitaux de Brabois /ID# 170855
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54500, France
CH Bretagne Atlantique /ID# 200191
Vannes, Morbihan, 56017, France
CHR Metz-Thionville - Hopital Bel-Air /ID# 170722
Thionville, Moselle, 57100, France
IUCT Oncopole /ID# 170749
Toulouse, Occitanie, 31059, France
AP-HP - Hopital Bicetre /ID# 170747
Le Kremlin-Bicêtre, Paris, 94270, France
Hopital de la Conception /ID# 201981
Marseille, Provence-Alpes-Côte d'Azur Region, 13005, France
Centre Hospitalier de la Cote Basque /ID# 170735
Bayonne, Pyrenees-Atlantiques, 64100, France
Centre Leon Berard /ID# 170018
Lyon, Rhone, 69373, France
Clinique Victor Hugo /ID# 169973
Le Mans, Sarthe, 72000, France
Centre Hospitalier du Mans /ID# 169451
Le Mans, Sarthe, 72037, France
Hopital de Melun /ID# 202569
Melun, Seine-et-Marne, 77011, France
Centre Henri Becquerel /ID# 169948
Rouen, Seine-Maritime, 76038, France
CHU Amiens-Picardie Site Sud /ID# 170724
Amiens, Somme, 80054, France
Institut Gustave Roussy /ID# 202436
Villejuif, Val-de-Marne, 94805, France
CHU Poitiers - La miletrie /ID# 169470
Poitiers, Vienne, 86000, France
CHI POISSY - Saint-Germain-en-Laye /ID# 169966
Saint-Germain-en-Laye, Yvelines, 78100, France
Ch Agen /Id# 170742
Agen, 47923, France
CH Victor Dupouy /ID# 169946
Argenteuil, 95100, France
Ch Blois /Id# 170727
Blois, 41016, France
CHRU de Brest - Hopital Morvan /ID# 169457
Brest, 29200, France
CHU de CAEN - Hopital de la Cote de Nacre /ID# 169941
Caen, 14033, France
Hopital Prive Sevigne /Id# 170718
Cesson-Sévigné, 35510, France
Medipole de Savoie /ID# 169454
Challes-les-Eaux, 73190, France
CH William Morey /ID# 169939
Chalon-sur-Saône, 71321, France
Centre Hospitalier de CHOLET /ID# 171215
Cholet, 49300, France
Hopital d'Instruction des Armées PERCY /ID# 170740
Clamart, 92141, France
Centre Joseph BELOT /ID# 170853
Désertines, 03030, France
CH Annecy Genevois - Site Annecy /ID# 200826
Epagny Metz Tessy, 74370, France
Centre Hospitalier de Versailles André Mignot /ID# 169950
Le Chesnay, 78150, France
CH Libourne - Hopital Robert Boulin /ID# 170739
Libourne, 33500, France
Hopital Saint Vincent de Paul /ID# 169956
Lille, 59020, France
Clinique de la Sauvegarde /ID# 169904
Lyon, 69009, France
CH Princesse Grace /ID# 200196
Monaco, 98000, France
CH Mont de MARSAN /ID# 169955
Mont-de-Marsan, 40024, France
Ch Mulhouse /Id# 170726
Mulhouse, 68100, France
Polyclinique le LANGUEDOC /ID# 169925
Narbonne, 11100, France
Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 169453
Orléans, 45067, France
Hôpital Saint-Louis /ID# 170856
Paris, 75010, France
Centre Hospitalier de Perpignan /ID# 170743
Perpignan, 66000, France
CH Périgueux /ID# 169458
Périgueux, 24019, France
CH Saint-Brieuc /ID# 171076
Saint-Brieuc, 22000, France
Hopital Nord Franche Comté /ID# 170744
Trévenans, 90400, France
Hopital Avicenne - APHP /ID# 169940
Bobigny, Île-de-France Region, 93000, France
Hopital Pitie Salpetriere /ID# 169974
Paris, Île-de-France Region, 75013, France
Related Links
MeSH Terms
Conditions
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 24, 2018
First Posted
January 30, 2018
Study Start
March 9, 2018
Primary Completion
June 1, 2026
Study Completion
June 1, 2026
Last Updated
July 16, 2025
Record last verified: 2025-07